Additionally, as a therapeutic approach, we previously have demonstrated that adoptively transferred Nr2f6 siRNA-silenced polyclonal CD3+ T cells act as an adjuvant for the established αPD-L1 immune checkpoint in the mouse B16-OVA tumor model [30]. This evidence concerns the gene NR2F6 and neoplasm.